Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Tremelimumab, and Lenvatinib in Unresectable Hepatocellular Carcinoma
NCT07081633Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab, tremelimumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Aug 2025; status: active, not recruiting.
02
Drugs
durvalumabtremelimumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07081633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081633.